首页> 外文期刊>Journal of Ocular Pharmacology and Therapeutics >Unusual Pharmacokinetics of Intravitreal and Systemic Voriconazole in a Patient with Scedosporium Apiospermum Endophthalmitis
【24h】

Unusual Pharmacokinetics of Intravitreal and Systemic Voriconazole in a Patient with Scedosporium Apiospermum Endophthalmitis

机译:玻璃体和全身性伏立康唑在Scedosporium Apiospermum眼内炎患者中的异常药代动力学

获取原文
获取原文并翻译 | 示例
       

摘要

In this paper, we report a case of a post-traumatic Scedosporium endophthalmitis treated with a posterior vitrectomy, followed by intravitreal injections and systemic voriconazole. This is the second documented case of S. apiospermum endophthalmitis treated with voriconazole and the first case with intravitreal injections of voriconazole. A 29-year-old man developed endophthalmitis after being struck in the left eye by a chip from a swimming pool pump. Despite 3 weeks of prophylactic antibiotherapy, his visual acuity remained only for the perception of light and vitreous inflammation increased. A creamy-white fungal mass grew at the inferior peripheral retina and pars plana. The fungus was identified as S. apiospermum. Oral voriconazole, at 200 mg twice-daily, did not bring the infection under control, considering the low plasma and intravitreal concentrations. Before steady-state plasma voriconazole concentrations reached an efficacy level greater than minimum inhibitory concentration of Scedosporium, intravitreal injections of 64 ug/0.1 mL of voriconazole were initiated twice-weekly for 3 weeks. Administration of higher intravenous voriconazole doses (6 mg/kg b.i.d.) for 6 weeks was needed to achieve an antifungal effect without systemic dissemination.
机译:在本文中,我们报道了玻璃体后切除,玻璃体内注射和全身伏立康唑治疗的创伤后硬皮孢菌性眼内炎一例。这是用伏立康唑治疗的第二例记载的apispermum眼内炎,也是第一例玻璃体内注射伏立康唑的病例。一名29岁的男子在被游泳池水泵的碎屑击中左眼后发展为眼内炎。尽管进行了3周的预防性生物治疗,但他的视力仍然仅存在于对光和玻璃体炎症的感知上。乳白色真菌团块生长在周围的下部视网膜和平面上。该真菌被鉴定为api.perospermum。考虑到血浆和玻璃体内浓度低,口服伏立康唑(每日两次)200 mg,不能使感染得到控制。在稳态血浆伏立康唑浓度达到的功效水平大于Scedosporium的最低抑制浓度之前,每周两次开始玻璃体内注射64 ug / 0.1 mL伏立康唑,持续3周。需要在6周内服用较高剂量的伏立康唑静脉内剂量(6 mg / kg b.i.d.)以达到抗真菌作用,而无需全身传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号